Neurizon Therapeutics Limited has released a press release.
DNDi contract extension for PharmAust subsidiary Epichem
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- First Patient Dosed in MND Phase 1/2 Trial
- First Patient in US Canine Cancer Trials Begins Treatment
- Update on PharmAust Canine Cancer Trials
- PharmAust Clinical Trials Update
- PharmAust receives $210k prepayment of forecast R&D rebate
Later from Neurizon Therapeutics
- MND Trial Completes Enrolment of First Patient Cohort
- PharmAust Canine Trial Update
- PharmAust Canine Trial Update clarification
- MND Trial Successfully Completes First Patient Cohort
- PharmAust Progresses to Elevated Doses in MND Patients
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics